Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7684A plus etoposide/platinum versus atezolizumab plus etoposide/platinum in first-line extensive-stage small cell lung cancer
jRCT2021220008Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of vibostolimab + pembrolizumab, atezolizumab, etoposide, cisplatin and carboplatin in small cell lung cancer (SCLC) (2 arms), sponsored by Merck & Co. Primary endpoint: Overall Survival. Started Jul 2022; status: completed.
02
Drugs
vibostolimab + pembrolizumabatezolizumabetoposidecisplatincarboplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2021220008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021220008.